Literature DB >> 11060673

Recent progress in antiviral chemotherapy for respiratory syncytial virus infections.

S Shigeta1.   

Abstract

The recent progress in antiviral chemotherapy against respiratory syncytial virus (RSV) infections was reviewed. RSV infections among high risk individuals, such as premature babies, infants with congenital disease of cardiopulmonary system or immune system and the aged, hospitalised patients with immunosuppressed status are threatened, with high mortality rates and thus need anti-viral chemotherapy. Clinical efficacy of ribavirin and humanized monoclonal antibody (mAb) against RSV infections as well as experimental reports of novel anti-RSV compounds under investigation such as membrane fusion inhibitors were introduced.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11060673     DOI： 10.1517/13543784.9.2.221

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  10 in total

1.  RFI-641, a potent respiratory syncytial virus inhibitor.

Authors:  Clayton C Huntley; William J Weiss; Anna Gazumyan; Aron Buklan; Boris Feld; William Hu; Thomas R Jones; Timothy Murphy; Antonia A Nikitenko; Bryan O'Hara; Gregory Prince; Susan Quartuccio; Yuri E Raifeld; Philip Wyde; John F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Molecular and clinical characteristics of respiratory syncytial virus infections in hospitalized children.

Authors:  R Mentel; U Ilgert; U Wegner; K Zimmerman; R Bruns; L Gürtler
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

4.  Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro.

Authors:  Zhanding Cui; Dengliang Li; Yinli Xie; Kai Wang; Ying Zhang; Guohua Li; Qian Zhang; Xiaoxueying Chen; Yue Teng; Shihui Zhao; Jiang Shao; Fan Xingmeng; Yanli Zhao; Dongju Du; Yanbing Guo; Hailong Huang; Hao Dong; Guixue Hu; Shuang Zhang; Yongkun Zhao
Journal:  Antiviral Res       Date:  2020-06-21       Impact factor: 5.970

5.  Efficacy and Safety of a Quadruple Regimen Compared with Triple Regimens in Patients with Mycophenolic Acid-Related Gastrointestinal Complications After Renal Transplantation: A Short-Term Single-Center Study.

Authors:  Zhiguo Peng; Wanhua Xian; Huaibin Sun; Engang Li; Lina Geng; Jun Tian
Journal:  Ann Transplant       Date:  2020-02-28       Impact factor: 1.530

6.  Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.

Authors:  Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Hideki Hasegawa; Noriyo Nagata; Naoko Iwata; Ichiro Kurane
Journal:  Antiviral Res       Date:  2005-02-19       Impact factor: 5.970

7.  Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.

Authors:  Dale L Barnard; Craig W Day; Kevin Bailey; Matthew Heiner; Robert Montgomery; Larry Lauridsen; Scott Winslow; Justin Hoopes; Joseph K-K Li; Jongdae Lee; Dennis A Carson; Howard B Cottam; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-03-24       Impact factor: 5.970

Review 8.  Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy.

Authors:  Claudia Soledad Sepúlveda; Cybele Carina García; Elsa Beatriz Damonte
Journal:  Microorganisms       Date:  2022-08-12

9.  In Vitro and in Vivo Antiviral Activity of Mizoribine Against Foot-And-Mouth Disease Virus.

Authors:  Shi-Fang Li; Mei-Jiao Gong; Yue-Feng Sun; Jun-Jun Shao; Yong-Guang Zhang; Hui-Yun Chang
Journal:  Molecules       Date:  2019-05-03       Impact factor: 4.411

10.  Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines.

Authors:  Chia Feng Yeh; Kuo Chih Wang; Lien Chai Chiang; Den En Shieh; Ming Hong Yen; Jung San Chang
Journal:  J Ethnopharmacol       Date:  2013-04-30       Impact factor: 4.360
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.